Gregory K. Webster is a senior principal research scientist with AbbVie Inc.'s Global Analytical Research and Development. He obtained his BS in chemistry from St. Xavier College, USA, MS in analytical chemistry from Governors State University, USA, and PhD in analytical chemistry from Northern Illinois University. Dr. Webster's industrial career spans an employment history with several major pharmaceutical companies. His first book with Pan Stanford Publishing, Supercritical Fluid Chromatography: Advances and Applications in Pharmaceutical Analysis, was published in 2014.

Robert G. Bell is president of Drug and Biotechnology Development LLC, USA, a consultancy to the pharmaceutical industry and academia for biological, drug, and device development. He received his education from the University of Florida and has worked with the pharmaceutical industry for over 30 years. Dr. Bell is adjunct faculty at Virginia Commonwealth University and the University of Florida College of Pharmacy and a member of the Council of Experts, General Chapters-Biological Analysis for United States Pharmacopeia.

J. Derek Jackson is director of Analytical Development at Flexion Therapeutics Inc, USA. He earned his BS and MA in chemistry from the College of William and Mary in Virginia. Derek has been engaged in all stages of pharmaceutical discovery, research, and development for 20 years, in both large pharma and small- to midcap biotech companies.

Introduction. Solubility determination for pharmaceutical API. Use of surfactants in dissolution testing. Intrinsic dissolution evaluation of poorly soluble drugs. Oral delivery of poorly soluble drugs. A staged approach to pharmaceutical dissolution testing. Development and application of in vitro two-phase dissolution method for poorly water soluble drugs. The use of Apparatus 3 in dissolution testing of poorly soluble drug formulations. Use of Apparatus 4 in dissolution testing, including sparingly and poorly soluble drugs. Dissolution of nanoparticle drug formulations. Dissolution of lipid based drug formulations. Dissolution of stabilized amorphous drug formulations. Dissolution of pharmaceutical suspensions. Dissolution testing of poorly soluble drugs: 'Biorelevant dissolution'. Clinically relevant dissolution for low solubility immediate release products. The QbD approach to method development and validation for dissolution testing. Regulatory considerations in dissolution and drug release of BCS class II and IV compounds. Dissolution of liquid-filled capsules based formulations. Current and emerging non-compendial methods for dissolution testing.